NEW YORK – Guardant Health said Thursday that it has entered a multiyear strategic collaboration with Pfizer, under which it will support the development and commercialization of cancer therapies using its Guardant Infinity liquid biopsy platform.
Financial terms of the agreement were not disclosed.
One of the specific goals of the partnership includes evaluating the clinical utility of circulating tumor DNA as a surrogate endpoint to monitor therapy response using Guardant's methylation-based Reveal assay.
The collaboration will also provide Pfizer with access to Guardant’s liquid biopsy tests in China. In July 2022, the firm announced a strategic partnership with Adicon Holdings to offer Guardant tests to biopharma companies conducting clinical trials in the country.